Guerenne L, Beurlet S, Said M, Gorombei P, Le Pogam C, Guidez F, de la Grange P, Omidvar N, Vanneaux V, Mills K, Mufti GJ, Sarda-Mantel L, Noguera M-E, Pla M, Fenaux P, Padua RA, Chomienne C, Krief P.
GEP analysis validates high risk MDS and acute myeloid leukemia post MDS mice models and highlights novel dysregulated pathways.
J Hematol Oncol. 9: 5, 2016. PMID: 26817437
Le Pogam C, Patel S, Gorombei P, Guerenne L, Krief P, Bernasconi E, Tekin N, Sicre F, Schlageter M-E, Chopin M, Mathews V, West RR, PLA M, Fenaux P, Chomienne C, Padua RA.
DNA-mediated adjuvant immunotherapy extends survival in two different mouse models of myeloid malignancies.
Oncotarget 6:32:494-508, 2015. PMID: 26378812
Patel S, Guerenne L, Gorombei P, Omidvar N, Schlageter M, Alex AA, Ganesan S, West R, Adès L, Mathews V, Krief P, Pla M, Fenaux P, Chomienne C, Padua RA.
PVAX14-mediated add-on immunotherapy combined with arsenic trioxide and all-trans retinoic acid (ATO+ATRA) targeted therapy effectively increases survival of APL mice.
Blood Cancer Journal, Dec 11;5:e374. doi: 10.1038/bcj.2015.102 PMID: 26657197
Patel S, Guerenne L, Gorombei P, Omidvar N, Schlageter M, Alex AA, Ganesan S, West R, Adès L, Mathews V, Krief P, Pla M, Fenaux P, Chomienne C, Padua RA.
Supplementary Materials for pVAX14DNA-mediated add-on immunotherapy combined with arsenic trioxide and all-trans retinoic acid (ATO+ATRA) targeted therapy effectively increases survival of APL mice- Blood Cancer Journal (2015)
Beurlet S, Omidvar N,Gorombei P, Krief P, Le Pogam C, Setterblad N, de la Grange P, Leboeuf C, Janin A,Noguera M-E, Hervatin F, Sarda-Mantel L, Konopleva M, Andreeff M, Tu A, Fan AC, Felsher DW, Whetton A, Pla M, West R, Fenaux P, Chomienne C, Padua RA.
BCL-2 inhibition with ABT-737 prolongs survival in an NRAS/BCL-2 mouse model of AML by targeting primitive LSK and progenitor cells.
Blood 122: 2864-2876, 2013. PMID: 23943652
Pokorna K, Chopin M, Le Pogam C, Balitrand N, Reboul M, Cassinat B, Chomienne C, Padua RA, Pla M.
Tracking of oncogene positive cells in preclinical models: biomarker of long term drug efficacy.
Molecular and Cellular Probes 27:1-5, 2013. PMID: 22906630
Tracking the extramedullary PML-RAR-positive cell reservoirs in a preclinical model: Biomarker of long-term drug efficacy-
Elsevier (2012)
Furugaki K, Pokorna K, Le Pogam C, Aoki M, Reboul M, Bajzik V, Krief P, Janin A, Noguera ME, West R, Charron D, Chomienne C, Pla M, Moins-Teisserenc H, Padua RA.
DNA vaccination with all-trans retinoic acid treatment induces long-term survival and elicits specific immune responses requiring CD4+ and CD8+ T-cell activation in an acute promyelocytic leukemia mouse model.
Blood 15:653-6, 2010. PMID: 19965687
Omidvar N, Kogan S, Beurlet S, Le Pogam C, Janin A, West R, Noguera ME, Reboul M., Soulie A., Le Bœuf C, Setterblad N, Felsher D, Lagasse, E, Mohamedali A, Thomas NS, Fenaux P, Fountenay M, Pla M, Mufti GJ, Weissmann I, Chomienne C, Padua RA.
BCL-2 and mutant NRAS interact physically and functionally in a mouse model of progressive myelodysplasia.
Cancer Research 67:11657-67, 2007. PMID: 18089795
Rassool F, Gaymes T, Omidvar N, Brady N, Pla M, Reboul M, Lea N, Chomienne C, Thomas NS, Mufti GJ, Padua RA.
Reactive oxygen species, DNA damage and error-prone repair: a model for genomic instability with progression in myeloid leukemia?
Cancer Research 67:8762-71, 2007. PMID: 17875717
Robin M, Andreu-Gallien J, Schlageter M-H, Bengoufa D, Guillemot I,Pokorna K, Robert C, Larghero J, Rousselot P, Raffoux E, Dombret H, Fenaux P, Pla M, Charron D, Padua RA, Chomienne C.
Frequent antibody production against RARa in both APL mice and patients.
Blood 108:1972-1974, 2006. PMID: 16728697
Gaymes TJ, Padua RA, Pla M, Orr S, Omidvar N, Chomienne C, Mufti GJ, Rassool F.
Histone Deacetylase Inhibitors (HDI) cause excessive DNA Damage in leukemia cells: A Mechanism for leukemia-specific HDI Dependent Apoptosis?
Molecular Cancer Research, 4 :563-573, 2006. PMID: 16877702
PML-RARA-targeted DNA vaccine induces protective immunity in a mouse model of leukemia-
Nature Medicine (2003)
Cancer Vaccine Targets Leukemia-
Nature Medicine (2003)
Gorombei P, Guidez F, Ganesan S, Chiquet M, Pellagatti A, Goursaud L, Tekin N, Beurlet S, Patel S, Guerenne L, Le Pogam C, Setterblad N, de la Grange P, Boultwood J, Konopleva M, Andreeff N, West R, Pla M, Ades L, Fenaux P, Krief P, Chomienne C, Omidvar N, Padua RA. BCL-2 inhibitor ABT-737 effectively targets leukemia-initiating cells with differential regulation of relevant genes leading to extended survival in a NRAS/BCL-2 mouse model of high risk-myelodysplastic syndrome. Int. J. Mol. Sci., 22:10658, 2021. PMID: 34638998
Zhang Q, Riley-Gillis B, Han L, Jia Y, Lodi A, Zhang H, Ganesan S, Pan R, Konoplev SN, Sweeney SR, Ryan JA, Jitkova Y, Dunner K Jr, Grosskurth SE, Vijay P, Ghosh S, Lu C, Ma W, Kurtz S, Ruvolo VR, Ma H, Weng CC, Ramage CL, Baran N, Shi C, Cai T, Davis RE, Battula VL, Mi Y, Wang J, DiNardo CD, Andreeff M, Tyner JW, Schimmer A, Letai A, Padua RA, Bueso-Ramos CE, Tiziani S, Leverson J, Popovic R, Konopleva M. Activation of RAS/MAPK pathway confers MCL-1 mediated acquired resistance to BCL-2 inhibitor venetoclax in acute myeloid leukemia.Signal Transduct Target Ther 2022 Feb 21;7(1):51. doi: 10.1038/s41392-021-00870-3. PMID: 35185150
Français 
English (UK)